Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Emerging Roles for Serotonin in Regulating Metabolism: New Implications for an Ancient Molecule.

Yabut JM, Crane JD, Green AE, Keating DJ, Khan WI, Steinberg GR.

Endocr Rev. 2019 Aug 1;40(4):1092-1107. doi: 10.1210/er.2018-00283.

PMID:
30901029
2.

Role of transporters in the disposition of a novel β-lactamase inhibitor: relebactam (MK-7655).

Chan G, Houle R, Lin M, Yabut J, Cox K, Wu J, Chu X.

J Antimicrob Chemother. 2019 Jul 1;74(7):1894-1903. doi: 10.1093/jac/dkz101.

PMID:
30891606
3.

FGF21 does not require adipocyte AMP-activated protein kinase (AMPK) or the phosphorylation of acetyl-CoA carboxylase (ACC) to mediate improvements in whole-body glucose homeostasis.

Mottillo EP, Desjardins EM, Fritzen AM, Zou VZ, Crane JD, Yabut JM, Kiens B, Erion DM, Lanba A, Granneman JG, Talukdar S, Steinberg GR.

Mol Metab. 2017 Apr 5;6(6):471-481. doi: 10.1016/j.molmet.2017.04.001. eCollection 2017 Jun.

4.

Validation of a microdose probe drug cocktail for clinical drug interaction assessments for drug transporters and CYP3A.

Prueksaritanont T, Tatosian DA, Chu X, Railkar R, Evers R, Chavez-Eng C, Lutz R, Zeng W, Yabut J, Chan GH, Cai X, Latham AH, Hehman J, Stypinski D, Brejda J, Zhou C, Thornton B, Bateman KP, Fraser I, Stoch SA.

Clin Pharmacol Ther. 2017 Apr;101(4):519-530. doi: 10.1002/cpt.525. Epub 2016 Dec 10.

PMID:
27943276
5.

Generation and Characterization of a Breast Cancer Resistance Protein Humanized Mouse Model.

Dallas S, Salphati L, Gomez-Zepeda D, Wanek T, Chen L, Chu X, Kunta J, Mezler M, Menet MC, Chasseigneaux S, Declèves X, Langer O, Pierre E, DiLoreto K, Hoft C, Laplanche L, Pang J, Pereira T, Andonian C, Simic D, Rode A, Yabut J, Zhang X, Scheer N.

Mol Pharmacol. 2016 May;89(5):492-504. doi: 10.1124/mol.115.102079. Epub 2016 Feb 18.

PMID:
26893303
6.

Inhibiting peripheral serotonin synthesis reduces obesity and metabolic dysfunction by promoting brown adipose tissue thermogenesis.

Crane JD, Palanivel R, Mottillo EP, Bujak AL, Wang H, Ford RJ, Collins A, Blümer RM, Fullerton MD, Yabut JM, Kim JJ, Ghia JE, Hamza SM, Morrison KM, Schertzer JD, Dyck JR, Khan WI, Steinberg GR.

Nat Med. 2015 Feb;21(2):166-72. doi: 10.1038/nm.3766. Epub 2014 Dec 8.

7.

Evaluation of organic anion transporting polypeptide 1B1 and 1B3 humanized mice as a translational model to study the pharmacokinetics of statins.

Salphati L, Chu X, Chen L, Prasad B, Dallas S, Evers R, Mamaril-Fishman D, Geier EG, Kehler J, Kunta J, Mezler M, Laplanche L, Pang J, Rode A, Soars MG, Unadkat JD, van Waterschoot RA, Yabut J, Schinkel AH, Scheer N.

Drug Metab Dispos. 2014 Aug;42(8):1301-13. doi: 10.1124/dmd.114.057976. Epub 2014 May 22.

PMID:
24855184
8.

Variability in P-glycoprotein inhibitory potency (IC₅₀) using various in vitro experimental systems: implications for universal digoxin drug-drug interaction risk assessment decision criteria.

Bentz J, O'Connor MP, Bednarczyk D, Coleman J, Lee C, Palm J, Pak YA, Perloff ES, Reyner E, Balimane P, Brännström M, Chu X, Funk C, Guo A, Hanna I, Herédi-Szabó K, Hillgren K, Li L, Hollnack-Pusch E, Jamei M, Lin X, Mason AK, Neuhoff S, Patel A, Podila L, Plise E, Rajaraman G, Salphati L, Sands E, Taub ME, Taur JS, Weitz D, Wortelboer HM, Xia CQ, Xiao G, Yabut J, Yamagata T, Zhang L, Ellens H.

Drug Metab Dispos. 2013 Jul;41(7):1347-66. doi: 10.1124/dmd.112.050500. Epub 2013 Apr 25.

9.

Metabolic activation and major protein target of a 1-benzyl-3-carboxyazetidine sphingosine-1-phosphate-1 receptor agonist.

Aloysius H, Tong VW, Yabut J, Bradley SA, Shang J, Zou Y, Tschirret-Guth RA.

Chem Res Toxicol. 2012 Jul 16;25(7):1412-22. doi: 10.1021/tx300017s. Epub 2012 Jul 5.

PMID:
22765480
10.

Determining P-glycoprotein-drug interactions: evaluation of reconstituted P-glycoprotein in a liposomal system and LLC-MDR1 polarized cell monolayers.

Melchior DL, Sharom FJ, Evers R, Wright GE, Chu JW, Wright SE, Chu X, Yabut J.

J Pharmacol Toxicol Methods. 2012 Mar;65(2):64-74. doi: 10.1016/j.vascn.2012.02.002. Epub 2012 Feb 26.

11.

Characterization of multidrug resistance 1a/P-glycoprotein knockout rats generated by zinc finger nucleases.

Chu X, Zhang Z, Yabut J, Horwitz S, Levorse J, Li XQ, Zhu L, Lederman H, Ortiga R, Strauss J, Li X, Owens KA, Dragovic J, Vogt T, Evers R, Shin MK.

Mol Pharmacol. 2012 Feb;81(2):220-7. doi: 10.1124/mol.111.074179. Epub 2011 Nov 2.

PMID:
22049154
12.

Rifampin's acute inhibitory and chronic inductive drug interactions: experimental and model-based approaches to drug-drug interaction trial design.

Reitman ML, Chu X, Cai X, Yabut J, Venkatasubramanian R, Zajic S, Stone JA, Ding Y, Witter R, Gibson C, Roupe K, Evers R, Wagner JA, Stoch A.

Clin Pharmacol Ther. 2011 Feb;89(2):234-42. doi: 10.1038/clpt.2010.271. Epub 2010 Dec 29.

PMID:
21191377
13.

Identification of pregnane-X receptor target genes and coactivator and corepressor binding to promoter elements in human hepatocytes.

Hariparsad N, Chu X, Yabut J, Labhart P, Hartley DP, Dai X, Evers R.

Nucleic Acids Res. 2009 Mar;37(4):1160-73. doi: 10.1093/nar/gkn1047. Epub 2009 Jan 7.

14.

Attenuating pregnane X receptor (PXR) activation: a molecular modelling approach.

Gao YD, Olson SH, Balkovec JM, Zhu Y, Royo I, Yabut J, Evers R, Tan EY, Tang W, Hartley DP, Mosley RT.

Xenobiotica. 2007 Feb;37(2):124-38.

PMID:
17484516
15.

Transport of the dipeptidyl peptidase-4 inhibitor sitagliptin by human organic anion transporter 3, organic anion transporting polypeptide 4C1, and multidrug resistance P-glycoprotein.

Chu XY, Bleasby K, Yabut J, Cai X, Chan GH, Hafey MJ, Xu S, Bergman AJ, Braun MP, Dean DC, Evers R.

J Pharmacol Exp Ther. 2007 May;321(2):673-83. Epub 2007 Feb 21.

PMID:
17314201
16.

Identification of potential pharmacological and toxicological targets differentiating structural analogs by a combination of transcriptional profiling and promoter analysis in LS-180 and Caco-2 adenocarcinoma cell lines.

Hartley DP, Dai X, Yabut J, Chu X, Cheng O, Zhang T, He YD, Roberts C, Ulrich R, Evers R, Evans DC.

Pharmacogenet Genomics. 2006 Aug;16(8):579-99.

PMID:
16847427
17.

Characterization of mice lacking the multidrug resistance protein MRP2 (ABCC2).

Chu XY, Strauss JR, Mariano MA, Li J, Newton DJ, Cai X, Wang RW, Yabut J, Hartley DP, Evans DC, Evers R.

J Pharmacol Exp Ther. 2006 May;317(2):579-89. Epub 2006 Jan 18.

PMID:
16421286
18.

Inhibition of proteasome activity sensitizes dopamine neurons to protein alterations and oxidative stress.

Mytilineou C, McNaught KS, Shashidharan P, Yabut J, Baptiste RJ, Parnandi A, Olanow CW.

J Neural Transm (Vienna). 2004 Oct;111(10-11):1237-51.

PMID:
15480836
19.

Toxicity of glutathione depletion in mesencephalic cultures: a role for arachidonic acid and its lipoxygenase metabolites.

Kramer BC, Yabut JA, Cheong J, Jnobaptiste R, Robakis T, Olanow CW, Mytilineou C.

Eur J Neurosci. 2004 Jan;19(2):280-6.

PMID:
14725622
20.

Glutathione depletion and oxidative stress.

Mytilineou C, Kramer BC, Yabut JA.

Parkinsonism Relat Disord. 2002 Sep;8(6):385-7. Review.

PMID:
12217624
21.

Lipopolysaccharide prevents cell death caused by glutathione depletion: possible mechanisms of protection.

Kramer BC, Yabut JA, Cheong J, JnoBaptiste R, Robakis T, Olanow CW, Mytilineou C.

Neuroscience. 2002;114(2):361-72.

PMID:
12204205
22.

Impairment of the ubiquitin-proteasome system causes dopaminergic cell death and inclusion body formation in ventral mesencephalic cultures.

McNaught KS, Mytilineou C, Jnobaptiste R, Yabut J, Shashidharan P, Jennert P, Olanow CW.

J Neurochem. 2002 Apr;81(2):301-6.

23.

Mechanized enzymatic determination of triglycerides in serum.

Bucolo G, Yabut J, Chang TY.

Clin Chem. 1975 Mar;21(3):420-4.

Supplemental Content

Support Center